Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth

R. Sarzani, P. Marcucci, F. Salvi, M. Bordicchia, E. Espinosa, L. Mucci, B. Lorenzetti, D. Minardi, G. Muzzonigro, P. Dessì-Fulgheri, A. Rappelli

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objective: Cardiovascular peptides such as angiotensin II (Ang II) and atrial natriuretic peptide (ANP) have metabolic effects on adipose cells. These peptides might also regulate adipocyte proliferation and visceral adipose tissue (VAT) expansion. Well-differentiated and stabilized primary cultures of human visceral mature adipocytes (MA) and in vitro-differentiated preadipocytes (DPA) were used as a model to study regulation of VAT expansion. Methods: Adipocyte differentiation was evaluated by Oil Red O staining and antiperilipin antibodies. MA and DPA from intra- and retro-peritoneal depots were treated with increasing Ang II (with or without valsartan, a highly selective, competitive, 'surmountable' AT1 antagonist devoid of peroxisome proliferator-activated receptor γ agonistic activity) or ANP concentrations. Cell counts and bromodeoxyuridine incorporation were used to evaluate proliferation. Apoptosis was evaluated by Hoechst 33342 staining. 8-Bromo cyclic guanosine monophosphate (8Br-cGMP) was used to investigate ANP effects, and real-time PCR to evaluate Ang II and ANP receptors' expression. Results: Cell proliferation was progressively stimulated by increasing Ang II concentrations (starting at 10-11 M) and inhibited by ANP (already at 10-13 M) in both MA and DPA. Co-incubation with increasing Ang II concentrations and valsartan indicated that Ang II effects were AT1-mediated. Indeed, AT2 receptors were not expressed. Valsartan alone slightly inhibited basal proliferation indicating an autocrine/paracrine growth factor-like effect of endogenous, adipocyte-derived Ang II. 8Br-cGMP experiments indicated that the effects of ANP were mediated by the guanylyl cyclase type A receptor. Conclusion: A cell-culture model to study VAT growth showed stimulation by Ang II and inhibition by ANP at physiological concentrations. Because similar effects are likely to occur in vivo, Ang II and ANP might be important modulators of VAT expansion and associated metabolic and cardiovascular consequences.

Original languageEnglish
Pages (from-to)259-267
Number of pages9
JournalInternational Journal of Obesity
Volume32
Issue number2
DOIs
Publication statusPublished - Feb 2008

Fingerprint

atrial natriuretic peptide
angiotensin II
Atrial Natriuretic Factor
adipocytes
Adipocytes
Angiotensin II
Valsartan
Intra-Abdominal Fat
Growth
Tissue Expansion
adipose tissue
guanosine monophosphate
Cyclic GMP
Atrial Natriuretic Factor Receptors
peptides
Staining and Labeling
Natriuretic Agents
guanylate cyclase
Peptides
receptors

Keywords

  • Adipocytes
  • Angiotensin II
  • Atrial natriuretic peptide
  • Human
  • Visceral adipose tissue

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Endocrinology
  • Food Science
  • Endocrinology, Diabetes and Metabolism

Cite this

Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth. / Sarzani, R.; Marcucci, P.; Salvi, F.; Bordicchia, M.; Espinosa, E.; Mucci, L.; Lorenzetti, B.; Minardi, D.; Muzzonigro, G.; Dessì-Fulgheri, P.; Rappelli, A.

In: International Journal of Obesity, Vol. 32, No. 2, 02.2008, p. 259-267.

Research output: Contribution to journalArticle

Sarzani, R, Marcucci, P, Salvi, F, Bordicchia, M, Espinosa, E, Mucci, L, Lorenzetti, B, Minardi, D, Muzzonigro, G, Dessì-Fulgheri, P & Rappelli, A 2008, 'Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth', International Journal of Obesity, vol. 32, no. 2, pp. 259-267. https://doi.org/10.1038/sj.ijo.0803724
Sarzani, R. ; Marcucci, P. ; Salvi, F. ; Bordicchia, M. ; Espinosa, E. ; Mucci, L. ; Lorenzetti, B. ; Minardi, D. ; Muzzonigro, G. ; Dessì-Fulgheri, P. ; Rappelli, A. / Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth. In: International Journal of Obesity. 2008 ; Vol. 32, No. 2. pp. 259-267.
@article{a3bb59974e464140a82e191354c4d913,
title = "Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth",
abstract = "Objective: Cardiovascular peptides such as angiotensin II (Ang II) and atrial natriuretic peptide (ANP) have metabolic effects on adipose cells. These peptides might also regulate adipocyte proliferation and visceral adipose tissue (VAT) expansion. Well-differentiated and stabilized primary cultures of human visceral mature adipocytes (MA) and in vitro-differentiated preadipocytes (DPA) were used as a model to study regulation of VAT expansion. Methods: Adipocyte differentiation was evaluated by Oil Red O staining and antiperilipin antibodies. MA and DPA from intra- and retro-peritoneal depots were treated with increasing Ang II (with or without valsartan, a highly selective, competitive, 'surmountable' AT1 antagonist devoid of peroxisome proliferator-activated receptor γ agonistic activity) or ANP concentrations. Cell counts and bromodeoxyuridine incorporation were used to evaluate proliferation. Apoptosis was evaluated by Hoechst 33342 staining. 8-Bromo cyclic guanosine monophosphate (8Br-cGMP) was used to investigate ANP effects, and real-time PCR to evaluate Ang II and ANP receptors' expression. Results: Cell proliferation was progressively stimulated by increasing Ang II concentrations (starting at 10-11 M) and inhibited by ANP (already at 10-13 M) in both MA and DPA. Co-incubation with increasing Ang II concentrations and valsartan indicated that Ang II effects were AT1-mediated. Indeed, AT2 receptors were not expressed. Valsartan alone slightly inhibited basal proliferation indicating an autocrine/paracrine growth factor-like effect of endogenous, adipocyte-derived Ang II. 8Br-cGMP experiments indicated that the effects of ANP were mediated by the guanylyl cyclase type A receptor. Conclusion: A cell-culture model to study VAT growth showed stimulation by Ang II and inhibition by ANP at physiological concentrations. Because similar effects are likely to occur in vivo, Ang II and ANP might be important modulators of VAT expansion and associated metabolic and cardiovascular consequences.",
keywords = "Adipocytes, Angiotensin II, Atrial natriuretic peptide, Human, Visceral adipose tissue",
author = "R. Sarzani and P. Marcucci and F. Salvi and M. Bordicchia and E. Espinosa and L. Mucci and B. Lorenzetti and D. Minardi and G. Muzzonigro and P. Dess{\`i}-Fulgheri and A. Rappelli",
year = "2008",
month = "2",
doi = "10.1038/sj.ijo.0803724",
language = "English",
volume = "32",
pages = "259--267",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth

AU - Sarzani, R.

AU - Marcucci, P.

AU - Salvi, F.

AU - Bordicchia, M.

AU - Espinosa, E.

AU - Mucci, L.

AU - Lorenzetti, B.

AU - Minardi, D.

AU - Muzzonigro, G.

AU - Dessì-Fulgheri, P.

AU - Rappelli, A.

PY - 2008/2

Y1 - 2008/2

N2 - Objective: Cardiovascular peptides such as angiotensin II (Ang II) and atrial natriuretic peptide (ANP) have metabolic effects on adipose cells. These peptides might also regulate adipocyte proliferation and visceral adipose tissue (VAT) expansion. Well-differentiated and stabilized primary cultures of human visceral mature adipocytes (MA) and in vitro-differentiated preadipocytes (DPA) were used as a model to study regulation of VAT expansion. Methods: Adipocyte differentiation was evaluated by Oil Red O staining and antiperilipin antibodies. MA and DPA from intra- and retro-peritoneal depots were treated with increasing Ang II (with or without valsartan, a highly selective, competitive, 'surmountable' AT1 antagonist devoid of peroxisome proliferator-activated receptor γ agonistic activity) or ANP concentrations. Cell counts and bromodeoxyuridine incorporation were used to evaluate proliferation. Apoptosis was evaluated by Hoechst 33342 staining. 8-Bromo cyclic guanosine monophosphate (8Br-cGMP) was used to investigate ANP effects, and real-time PCR to evaluate Ang II and ANP receptors' expression. Results: Cell proliferation was progressively stimulated by increasing Ang II concentrations (starting at 10-11 M) and inhibited by ANP (already at 10-13 M) in both MA and DPA. Co-incubation with increasing Ang II concentrations and valsartan indicated that Ang II effects were AT1-mediated. Indeed, AT2 receptors were not expressed. Valsartan alone slightly inhibited basal proliferation indicating an autocrine/paracrine growth factor-like effect of endogenous, adipocyte-derived Ang II. 8Br-cGMP experiments indicated that the effects of ANP were mediated by the guanylyl cyclase type A receptor. Conclusion: A cell-culture model to study VAT growth showed stimulation by Ang II and inhibition by ANP at physiological concentrations. Because similar effects are likely to occur in vivo, Ang II and ANP might be important modulators of VAT expansion and associated metabolic and cardiovascular consequences.

AB - Objective: Cardiovascular peptides such as angiotensin II (Ang II) and atrial natriuretic peptide (ANP) have metabolic effects on adipose cells. These peptides might also regulate adipocyte proliferation and visceral adipose tissue (VAT) expansion. Well-differentiated and stabilized primary cultures of human visceral mature adipocytes (MA) and in vitro-differentiated preadipocytes (DPA) were used as a model to study regulation of VAT expansion. Methods: Adipocyte differentiation was evaluated by Oil Red O staining and antiperilipin antibodies. MA and DPA from intra- and retro-peritoneal depots were treated with increasing Ang II (with or without valsartan, a highly selective, competitive, 'surmountable' AT1 antagonist devoid of peroxisome proliferator-activated receptor γ agonistic activity) or ANP concentrations. Cell counts and bromodeoxyuridine incorporation were used to evaluate proliferation. Apoptosis was evaluated by Hoechst 33342 staining. 8-Bromo cyclic guanosine monophosphate (8Br-cGMP) was used to investigate ANP effects, and real-time PCR to evaluate Ang II and ANP receptors' expression. Results: Cell proliferation was progressively stimulated by increasing Ang II concentrations (starting at 10-11 M) and inhibited by ANP (already at 10-13 M) in both MA and DPA. Co-incubation with increasing Ang II concentrations and valsartan indicated that Ang II effects were AT1-mediated. Indeed, AT2 receptors were not expressed. Valsartan alone slightly inhibited basal proliferation indicating an autocrine/paracrine growth factor-like effect of endogenous, adipocyte-derived Ang II. 8Br-cGMP experiments indicated that the effects of ANP were mediated by the guanylyl cyclase type A receptor. Conclusion: A cell-culture model to study VAT growth showed stimulation by Ang II and inhibition by ANP at physiological concentrations. Because similar effects are likely to occur in vivo, Ang II and ANP might be important modulators of VAT expansion and associated metabolic and cardiovascular consequences.

KW - Adipocytes

KW - Angiotensin II

KW - Atrial natriuretic peptide

KW - Human

KW - Visceral adipose tissue

UR - http://www.scopus.com/inward/record.url?scp=39449127444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39449127444&partnerID=8YFLogxK

U2 - 10.1038/sj.ijo.0803724

DO - 10.1038/sj.ijo.0803724

M3 - Article

C2 - 17878892

AN - SCOPUS:39449127444

VL - 32

SP - 259

EP - 267

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - 2

ER -